Overview

Effect of Administration of the Combination Bezafibrate More Berberine on Lipid Profile in Patients With Dyslipidemia

Status:
Unknown status

Trial end date:
2016-07-01

Target enrollment:

Participant gender:

Summary

Dyslipidemia, is a cardiovascular risk factor of great importance whose prevalence has increased over the last decade. Part of the components of metabolic syndrome and consensus so far contemplated to increased triglycerides and reduced HDL-C as part of the elements for classification, which includes mixed dyslipidemia. Currently fibrates, such as bezafibrate, are drugs whose utility in treating hypertriglyceridemia is fully proven, besides reducing the risk of coronary disease. However, although this treatment is safe, it is not without risks; with increased prevalence of adverse effects as the dose thereof is increased or joins combination with a statin drug for the treatment of mixed dyslipidemia long term. Among the alternative therapies is berberine, which to reduce cholesterol and triglycerides may be useful in combination with the bezafribrato in the treatment of mixed dyslipidemia and as an option with lower cost and lower frequency of adverse events.

Phase:

Phase 2

Details

Lead Sponsor:

University of Guadalajara

Treatments:

Bezafibrate
Magnesium Oxide